Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study

被引：1

作者：

le Coutre, Philipp D. ^{[1
]}

Turkina, Anna ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Ceglarek, Bernadeta ^{[4
]}

Alimena, Giuliana ^{[5
]}

Al-Ali, Haifa Kathrin ^{[6
]}

Shen, Zhixiang ^{[7
]}

Jootar, Saengsuree ^{[8
]}

Smith, Graeme ^{[9
]}

De Souza, Carmino Antonio ^{[10
,11
]}

Dorlhiac-Llacer, Pedro Enrique ^{[12
]}

Rizzieri, David A. ^{[13
]}

Szczudlo, Tomasz ^{[14
]}

Berton, Myriam ^{[15
]}

Wang, Jim ^{[16
]}

Wang, Si-Tien ^{[17
]}

Nicolini, Franck Emmanuel ^{[18
]}

机构：

[1] Humboldt Univ, Charite, Dept Hematol & Oncol, Berlin, Germany

[2] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Inst Hematol & Transfufzjol, Warsaw, Poland

[5] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[6] Univ Leipzig, Dept Hematol Oncol, Leipzig, Germany

[7] Shanghai Ruijin Hosp, Shanghai, Peoples R China

[8] Mahidol Univ, BMT Program, Ramathibodi Hosp, Bangkok 10700, Thailand

[9] Dept Haematol, Leeds, W Yorkshire, England

[10] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Sao Paulo, Brazil

[11] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil

[12] FMUSP, Hosp Clin, Sao Paulo, Brazil

[13] Duke Univ, Med Ctr, Durham, NC USA

[14] Novartis Pharmaceut, Florham Pk, NJ USA

[15] Novartis Pharmaceut, Basel, Switzerland

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Anal Grp Inc, Boston, MA USA

[18] Hop Edouard Herriot, Lyon, France

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1272 / 1273

页数：2

共 50 条

[21] Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party
Lee, Jeong-Ok
Kim, Inho
Chung, Joo-Seop
Kim, Yeo-Kyeoung
Yhim, Ho-Young
Kim, Dae-Young
Do, Young-Rok
Seong, Chu-Myong
Nam, Seung-Hyun
Kim, Sung-Hyun
Lee, Jae-Hoon
Park, Jinny
Kim, Jin Seok
Min, Yoo-Hong
Sohn, Sang Kyun
Joo, Young Don
Bae, Sung-Hwa
Oh, Sukjoong
Zang, Dae Young
Lee, Hong Ghi
Yoon, Sung-Soo
Park, Seonyang
BLOOD, 2012, 120 (21)
[22] Expanding Nilotinib Access in Clinical Trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph plus ) chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): Updated safety analysis
Nicolini, F. E.
Alimena, G.
Al-Ali, H.
Zaritskey, A. Y.
Shen, Z.
Jootar, S.
Smith, G.
Hsu, Y.
Veronese, M. L.
Rizzieri, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[23] Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
Takahashi N.
Miura M.
Kuroki J.
Mitani K.
Kitabayashi A.
Sasaki O.
Kimura H.
Imai K.
Tsukamoto N.
Noji H.
Kondo T.
Motegi M.
Kato Y.
Mita M.
Saito H.
Yoshida C.
Torimoto Y.
Kimura T.
Wano Y.
Nomura J.
Yamamoto S.
Mayama K.
Honma R.
Sugawara T.
Sato S.
Shinagawa A.
Abumiya M.
Niioka T.
Harigae H.
Sawada K.
Biomarker Research, 2 (1)
[24] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
Rosti, G.
le Coutre, P.
Bhalla, K.
Giles, F.
Ossenkoppele, G.
Hochhaus, A.
Gattermann, N.
Haque, A.
Weitzman, A.
Baccarani, M.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[25] Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials)
Powell, Bayard L.
Khoury, Hanna Jean
Lipton, Jeffrey H.
Rizzieri, David A.
Williams, Denise
Turner, A. Robert
BLOOD, 2009, 114 (22) : 1277 - 1277
[26] BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Kim, D.
Saglio, G.
Martinelli, G.
Shou, Y.
Stein, A. M.
Woodman, R. C.
Kantarjian, H.
Hughes, T. P.
Radich, J. P.
Hochhaus, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES
Saglio, S.
Hughes, T.
Kim, D. W.
Hanfstein, B.
Gottardi, E.
Branford, S.
Goh, H.
Beppu, L.
Soverini, S.
Shou, Y.
Stein, A.
Woodman, R.
Kantarjian, H.
Radich, J.
Hochhaus, A.
Martinelli, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 342 - 343
[28] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
Hoyle, Martin
Rogers, Gabriel
Moxham, Tiffany
Liu, Zulian
Stein, Ken
VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
[29] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
le Coutre, Philipp
Bhalla, Kapil
Giles, Francis
Baccarani, Michele
Ossenkoppele, Gert J.
Hochhaus, Andreas
Gattermann, Norbert
Rafferty, Teresa
Haque, Ariful
Weitzman, Aaron
Kantarjian, Hagop
BLOOD, 2006, 108 (11) : 53A - 53A
[30] COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSUS DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML)
Niu, X.
Hay, J.
VALUE IN HEALTH, 2012, 15 (04) : A209 - A210

← 1 2 3 4 5 →